Drug Profile
Tradipitant - Vanda Pharmaceuticals
Alternative Names: LY-686017; VLY 686Latest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
- Class Anti-inflammatories; Antipruritics; Antivirals; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Gastrokinetics; Pyridines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Gastroparesis
- Phase III Atopic dermatitis; COVID 2019 infections; Motion sickness
- Phase II Pruritus
- Discontinued Alcoholism; Social phobia
Most Recent Events
- 04 Dec 2023 Preregistration for Gastroparesis in USA (PO)
- 04 Dec 2023 FDA assigns PDUFA action date of (18/09/2024) for tradipitant for Gastroparesis
- 21 Jun 2023 Pooled efficacy data from the phase III VP-VLY-686-3301 and VP-VLY-686-2301 trials in Gastroparesis presented at the Digestive Disease Week 2023 (DDW-2023)